Approval · Notice of Compliance 29310 · 2022
LEQVIO: Notice of Compliance 29310
Issued October 26, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29310
- Date
- October 26, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of Sandoz GmbH, Langkampfen, Austria, as an alternative drug product manufacturing and an alternative primary packaging site. Change in part of the (primary) packaging material not in contact with the finished product formulation.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LEQVIO | Not yet assigned | — |
Medicinal ingredients
- INCLISIRAN SODIUM 284 MG per 1.5ML